PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1370641
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1370641
Global Particle Therapy Market will witness over 8.7% CAGR between 2023 and 2032. The market is expected to flourish due to the increasing adoption of cutting-edge particle therapy equipment by leading hospitals and health facilities. For instance, in September 2023, ION Beam Applications S.A. (IBA), a global frontrunner in particle accelerator technology and the foremost provider of proton therapy solutions for cancer treatment, officially inked the conclusive agreement with Medtechnica Ltd. This agreement paves the way for the installation of two state-of-the-art Proteus®ONE compact proton therapy systems at the Sourasky Medical Center, also known as Ichilov Hospital, in Tel Aviv, Israel.
These hospitals are choosing high-quality equipment from top manufacturers, which, in turn, fuels the particle therapy market growth. The precise and effective treatment capabilities of particle therapy are a key factor in this trend, as healthcare providers seek to offer the best possible care to their patients.
The overall Particle Therapy Market is classified based on product, cancer type, and region.
Cyclotrons segment will undergo significant development from 2023 to 2032. Cyclotrons play a pivotal role in cancer treatment by accelerating these particles to precise energies for effective therapies. As the medical community increasingly recognizes the precision and benefits of particle therapy, the demand for cyclotrons is on the rise, supporting the particle therapy market outlook. The demand for cyclotrons, which are integral in producing the necessary particles for proton and heavy ion therapy, is registering high growth due to the above-stated reasons.
The pediatric cancer segment will register a notable CAGR from 2023 to 2032. Particle therapy, including proton and heavy ion therapy, is gaining prominence for its precision and reduced side effects, making it an ideal choice for young cancer patients. As awareness grows about the advantages of particle therapy in treating pediatric cancers, the particle therapy market demand in this specialized field is on the rise.
Asia Pacific particle therapy market will showcase an appreciable CAGR from 2023 to 2032. Factors such as a growing population, increasing cancer incidence, and a greater awareness of the benefits of particle therapy are driving this demand. Asian countries are expanding their healthcare infrastructure to include proton and heavy ion therapy facilities, indicating a significant market growth trajectory in the Asia Pacific. For instance, in October 2023, in a joint statement, Hitachi, Ltd. and Hitachi Asia Ltd. disclosed the successful delivery of a proton therapy system to the National Cancer Centre Singapore ("NCCS"). This achievement marks a groundbreaking moment as Hitachi's inaugural proton therapy system to be operational for patient treatment in Southeast Asia.